Biosimilars are FDA-approved biologic medications used for treating many illnesses, including cancer. They are made with the same types of natural sources as the original or reference biologic they were compared to (in this case, HERCEPTIN® (trastuzumab)) and provide the same treatment benefits. Biosimilars must meet the FDA’s rigorous approval standards. This means patients and healthcare professionals can rely upon the safety and effectiveness of the biosimilar, just as they would the original product. The safety and effectiveness of trastuzumab products in pediatric patients have not been established.